Literature DB >> 31037509

Mucosal healing in inflammatory bowel disease: Expanding horizon.

Jimil Shah1, Manik Lal Thakur1, Usha Dutta2.   

Abstract

Management of inflammatory bowel diseases has witnessed paradigm shift from 5-aminosalicylic acid and glucocorticoids to various immunosuppressant and biological agents. Targets of therapy have also been changed drastically from symptomatic improvement to mucosal, histological healing, and recently transmural healing. Mucosal healing is associated with reduced need of steroid therapy, hospitalization, and surgery. However, whether mucosal healing alters the natural history of disease remains to be proven. Though assessment of mucosal healing is traditionally done by endoscopic examination, newer tests like fecal calprotectin, capsule endoscopy, and magnetic resonance enterography have also shown promising results. Various immunosuppressants and biologicals are the main therapy being used to achieve mucosal healing. This review focuses on the need for achieving mucosal healing, its long-term benefits, various methods and algorithm for diagnosis, and achievement of mucosal healing.

Entities:  

Keywords:  Histological healing; Inflammatory bowel disease; Mucosal healing; Target to treat approach

Mesh:

Substances:

Year:  2019        PMID: 31037509     DOI: 10.1007/s12664-019-00950-x

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  93 in total

1.  Serum amyloid A level correlated with endoscopic findings in patients with Crohn's disease-Possible biomarker for evaluating mucosal healing.

Authors:  Shunji Ishihara; Yasumasa Tada; Kousaku Kawashima; Masatoshi Kataoka; Hiroki Sonoyama; Noritsugu Yamashita; Akihiko Oka; Ryusaku Kusunoki; Nobuhiko Fukuba; Yoshiyuki Mishima; Naoki Oshima; Ichiro Moriyama; Takafumi Yuki; Yoshikazu Kinoshita
Journal:  Dig Liver Dis       Date:  2017-12-19       Impact factor: 4.088

2.  Beyond remission and mucosal healing in Crohn's disease. Exploring the deep with cross sectional imaging.

Authors:  Giovanni Maconi; Alessandro Armuzzi
Journal:  Dig Liver Dis       Date:  2017-05       Impact factor: 4.088

Review 3.  Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis.

Authors:  Brisas M Flores; Anthony O'Connor; Alan C Moss
Journal:  Gastrointest Endosc       Date:  2017-07-24       Impact factor: 9.427

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 5.  Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.

Authors:  A Cholapranee; G S Hazlewood; G G Kaplan; L Peyrin-Biroulet; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-03-22       Impact factor: 8.171

6.  Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.

Authors:  M Vecchi; G Meucci; P Gionchetti; M Beltrami; P Di Maurizio ; L Beretta; E Ganio; P Usai; M Campieri; G Fornaciari; R de Franchis
Journal:  Aliment Pharmacol Ther       Date:  2001-02       Impact factor: 8.171

7.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

8.  Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Authors:  William J Sandborn; Brian G Feagan; Douglas C Wolf; Geert D'Haens; Severine Vermeire; Stephen B Hanauer; Subrata Ghosh; Heather Smith; Matthew Cravets; Paul A Frohna; Richard Aranda; Sheila Gujrathi; Allan Olson
Journal:  N Engl J Med       Date:  2016-05-05       Impact factor: 91.245

9.  Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

Authors:  Julian Panés; William J Sandborn; Stefan Schreiber; Bruce E Sands; Séverine Vermeire; Geert D'Haens; Remo Panaccione; Peter D R Higgins; Jean-Frederic Colombel; Brian G Feagan; Gary Chan; Michele Moscariello; Wenjin Wang; Wojciech Niezychowski; Amy Marren; Paul Healey; Eric Maller
Journal:  Gut       Date:  2017-02-16       Impact factor: 23.059

10.  Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Authors:  William J Sandborn; Bal R Bhandari; Charles Randall; Ziad H Younes; Tomasz Romanczyk; Yan Xin; Emily Wendt; Hao Chai; Matt McKevitt; Sally Zhao; John S Sundy; Satish Keshav; Silvio Danese
Journal:  J Crohns Colitis       Date:  2018-08-29       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.